260 related articles for article (PubMed ID: 29396290)
1. Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria.
Velkov T; Gallardo-Godoy A; Swarbrick JD; Blaskovich MAT; Elliott AG; Han M; Thompson PE; Roberts KD; Huang JX; Becker B; Butler MS; Lash LH; Henriques ST; Nation RL; Sivanesan S; Sani MA; Separovic F; Mertens H; Bulach D; Seemann T; Owen J; Li J; Cooper MA
Cell Chem Biol; 2018 Apr; 25(4):380-391.e5. PubMed ID: 29396290
[TBL] [Abstract][Full Text] [Related]
2. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria.
Becker B; Butler MS; Hansford KA; Gallardo-Godoy A; Elliott AG; Huang JX; Edwards DJ; Blaskovich MAT; Cooper MA
Bioorg Med Chem Lett; 2017 Jun; 27(11):2407-2409. PubMed ID: 28454673
[TBL] [Abstract][Full Text] [Related]
4. Octapeptin C4 and polymyxin resistance occur via distinct pathways in an epidemic XDR Klebsiella pneumoniae ST258 isolate.
Pitt ME; Cao MD; Butler MS; Ramu S; Ganesamoorthy D; Blaskovich MAT; Coin LJM; Cooper MA
J Antimicrob Chemother; 2019 Mar; 74(3):582-593. PubMed ID: 30445429
[TBL] [Abstract][Full Text] [Related]
5. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
[TBL] [Abstract][Full Text] [Related]
6. Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.
Schneider-Futschik EK; Paulin OKA; Hoyer D; Roberts KD; Ziogas J; Baker MA; Karas J; Li J; Velkov T
ACS Infect Dis; 2018 May; 4(5):646-655. PubMed ID: 29566483
[TBL] [Abstract][Full Text] [Related]
7. Rediscovering the octapeptins.
Velkov T; Roberts KD; Li J
Nat Prod Rep; 2017 Mar; 34(3):295-309. PubMed ID: 28180225
[TBL] [Abstract][Full Text] [Related]
8. Battacin (Octapeptin B5), a new cyclic lipopeptide antibiotic from Paenibacillus tianmuensis active against multidrug-resistant Gram-negative bacteria.
Qian CD; Wu XC; Teng Y; Zhao WP; Li O; Fang SG; Huang ZH; Gao HC
Antimicrob Agents Chemother; 2012 Mar; 56(3):1458-65. PubMed ID: 22183171
[TBL] [Abstract][Full Text] [Related]
9. Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes.
Han ML; Shen HH; Hansford KA; Schneider EK; Sivanesan S; Roberts KD; Thompson PE; Le Brun AP; Zhu Y; Sani MA; Separovic F; Blaskovich MAT; Baker MA; Moskowitz SM; Cooper MA; Li J; Velkov T
ACS Infect Dis; 2017 Aug; 3(8):606-619. PubMed ID: 28695731
[TBL] [Abstract][Full Text] [Related]
10. Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration.
Papadopoulos A; Ribera A; Mavrogenis AF; Rodriguez-Pardo D; Bonnet E; Salles MJ; Dolores Del Toro M; Nguyen S; Blanco-García A; Skaliczki G; Soriano A; Benito N; Petersdorf S; Pasticci MB; Tattevin P; Tufan ZK; Chan M; O'Connell N; Pantazis N; Kyprianou A; Pigrau C; Megaloikonomos PD; Senneville E; Ariza J; Papagelopoulos PJ; Giannitsioti E;
Int J Antimicrob Agents; 2019 Mar; 53(3):294-301. PubMed ID: 30395988
[TBL] [Abstract][Full Text] [Related]
11. Octapeptins: Lipopeptide Antibiotics against Multidrug-Resistant Superbugs.
Abou Fayad A; Herrmann J; Müller R
Cell Chem Biol; 2018 Apr; 25(4):351-353. PubMed ID: 29677485
[TBL] [Abstract][Full Text] [Related]
12. Simulations of octapeptin-outer membrane interactions reveal conformational flexibility is linked to antimicrobial potency.
Jiang X; Yang K; Yuan B; Gong B; Wan L; Patil NA; Swarbrick JD; Roberts KD; Schreiber F; Wang L; Velkov T; Li J
J Biol Chem; 2020 Nov; 295(47):15902-15912. PubMed ID: 32913118
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
[TBL] [Abstract][Full Text] [Related]
14. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
[TBL] [Abstract][Full Text] [Related]
15. [Colistin in the post-antibiotic era].
Aguayo A; Mella S; Riedel G; Bello H; Domínguez M; González-Rocha G
Rev Chilena Infectol; 2016 Apr; 33(2):166-76. PubMed ID: 27314994
[TBL] [Abstract][Full Text] [Related]
16. Dilipid ultrashort cationic lipopeptides as adjuvants for chloramphenicol and other conventional antibiotics against Gram-negative bacteria.
Domalaon R; Brizuela M; Eisner B; Findlay B; Zhanel GG; Schweizer F
Amino Acids; 2019 Mar; 51(3):383-393. PubMed ID: 30392097
[TBL] [Abstract][Full Text] [Related]
17. Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?
Ozsurekci Y; Aykac K; Cengiz AB; Bayhan C; Sancak B; Karadag Oncel E; Kara A; Ceyhan M
Diagn Microbiol Infect Dis; 2016 Jun; 85(2):233-8. PubMed ID: 27041107
[TBL] [Abstract][Full Text] [Related]
18. Clinical Use of Polymyxin B.
Rigatto MH; Falci DR; Zavascki AP
Adv Exp Med Biol; 2019; 1145():197-218. PubMed ID: 31364080
[TBL] [Abstract][Full Text] [Related]
19. Colistin: still a lifesaver for the 21st century?
Karaiskos I; Souli M; Galani I; Giamarellou H
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):59-71. PubMed ID: 27573251
[TBL] [Abstract][Full Text] [Related]
20.
Purnapatre KP; Rao M; Pandya M; Khanna A; Chaira T; Bambal R; Upadhyay DJ; Masuda N
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
